|Global Cardiomyopathy Therapies Markets Through 2019-2023; Dominated by AstraZeneca, Merck, Pfizer and Sanofi - ResearchAndMarkets.com|
|Thursday, 10 January 2019 04:06|
Jan. 10, 2019 13:47 UTC
Global Cardiomyopathy Therapies Markets Through 2019-2023; Dominated by AstraZeneca, Merck, Pfizer and Sanofi - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)-- The "Global Cardiomyopathy Therapies Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
The cardiomyopathy therapies market will register a CAGR of almost 2% by 2023.
Advent of genomic medicine to push market growth during the forecast period
Cardiomyopathy is one of the major causes of heart failure. Genomic medicine is an emerging field in healthcare, it uses gene-related information of an individual.
Initiative to increase awareness about disease
There has been an increase in initiatives to spread awareness about cardiomyopathy among people in the last few years.
High cost of treatment
Cardiomyopathy makes it difficult for the heart to pump blood to rest of the body. The condition can be treated by surgically implanting devices within the heart, these devices are quite expensive. This high cost associated with the treatment of cardiomyopathy may pose a challenge to the market.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
PART 06: FIVE FORCES ANALYSIS
PART 07: MARKET SEGMENTATION BY TYPE
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY PRODUCT
PART 10: GEOGRAPHIC LANDSCAPE
PART 11: DRIVERS AND CHALLENGES
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
PART 14: VENDOR ANALYSIS
For more information about this report visit https://www.researchandmarkets.com/research/t8vxmp/global?w=4
Source: Research and Markets